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l-Glutamate and its receptors (GluRs) play a key role in excitatory neurotransmission within the mammalian central nervous
system (CNS). Impaired regulation of GluRs has also been implicated in various neurological disorders. GluRs are classified into
two major groups: ionotropic GluRs (iGluRs), which are ligand-gated ion channels, and metabotropic GluRs (mGluRs), which are
coupled to heterotrimeric guanosine nucleotide binding proteins (G-proteins). Positron emission tomography (PET) and single
photon emission computed tomography (SPECT) imaging of GluRs could provide a novel view of CNS function and of a range of
brain disorders, potentially leading to the development of new drug therapies. Although no satisfactory imaging agents have yet
been developed for iGluRs, several PET ligands for mGluRs have been successfully employed in clinical studies.This paper reviews
current progress towards the development of PET and SPECT probes for GluRs.
1. Introduction
l-Glutamate is the primary endogenous excitatory neuro-
transmitter and glutamate receptors (GluRs) are implicated
in a range of neurological functions within the mammalian
central nervous system (CNS). Two distinct groups of GluRs
have been identified: ionotropic receptors (iGluRs) and
metabotropic receptors (mGluRs). iGluRs form ligand-gated
ion channels and are classified into three subtypes based
on their pharmacological properties: NMDA (N-methyl-d-
aspartate receptors,NMDARs),AMPA (𝛼-amino-3-hydroxy-
5-methylisoxazole-4-proprionic acid) receptors, and kainate
receptors [1]. mGluRs are coupled to heterotrimeric guano-
sine nucleotide binding proteins (G-proteins) and include
eight receptor subtypes, classified into three groups accord-
ing to their sequence homology, signal transduction, and
pharmacological profiles; group I includes mGluR1 and
mGluR5, group II includes mGluR2 and mGluR3, and
group III includes mGluR4, mGluR6, mGluR7, and mGluR8
[2]. Impaired regulation of GluRs may be involved in the
pathophysiology of various brain disorders [3, 4]. Positron
emission tomography (PET) and single photon emission
computed tomography (SPECT) imaging for GluRs are con-
sidered to be powerful tools for the evaluation of excitatory
neurotransmission in the living brain, the study of the
pathophysiology of related neurological disorders, and the
quantification of GluR drug occupancy in vivo. To date, no
specific radioligands for in vivo visualization of iGluRs have
been identified. In contrast, there are several promising clini-
cally useful PET ligands formGluRs.This review summarizes
current progress towards the development of PET and SPECT
probes for GluRs, with a particular focus on NMDARs and
mGluRs.
2. NMDARs
The NMDARs are iGluRs that play key roles in processes
involving excitatory neurotransmission, including learn-
ing, memory, and synaptic plasticity [5, 6]. Dysregulation
of NMDARs has been identified in various neurologi-
cal diseases, including epilepsy, ischemia, stroke, Parkin-
son’s disease, Alzheimer’s disease, Huntington’s disease, and
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schizophrenia [4, 7, 8]. Activation of these receptors requires
binding of glutamate and glycine and removal of Mg2+
blockade by membrane depolarization. NMDAR channel
opening results in calcium influx into cells, followed by Ca2+-
dependent signal transduction cascades that modulate many
aspects of neuronal function [1, 9]. Functional NMDARs are
composed of twoNR1 subunits, together with either twoNR2
subunits or a combination of NR2 and NR3 subunits [10–
12]. NR1 subunits are ubiquitously distributed throughout
the brain. There are four types of the NR2 subunit (NR2A,
NR2B, NR2C, and NR2D), with distinct distributions in
the brain [13]. NR3 subunits can be activated by glycine
alone. NR3A is expressed in the cortex and brainstem, while
NR3B is distributed in the forebrain and cerebellum [14].
The glutamate binding site is present on the NR2 subunit,
whereas the glycine binding site is located on NR1 or NR3
[11, 15, 16]. Polyamines are allosteric potentiators of NMDARs
containing NR2B subunits, presumably through recognition
of the NR1 and NR2B dimer interface [17]. It is known
that aliphatic cyclic amine groups strongly inhibit NMDAR
activity in a noncompetitive and voltage-dependent manner
[18, 19]. Negative modulators of NR2B, including ifenprodil
and its derivatives, have been found to bind at the interface
between the NR1 and NR2B subunits [20]. The main strategy
for development of PET and SPECT ligands is the struc-
tural modification of NMDA receptor antagonists, including
channel blockers, glycine site antagonists, andNR2B negative
modulators. Because most competitive antagonists of the
glutamate binding site have shown low selectivity and poor
blood-brain barrier (BBB) permeability [1, 21], there are no
reported radioligands interacting with this region of the
NMDAR.
2.1. Imaging Probes for the NMDAR Channel Blocker Binding
Site. Open channel blockers of NMDARs, such as (+)-10,
11-dihydro-5-methyl-5H-dibenzo[a,d] cyclohepten-5,10-diy-
ldiammonium maleate (MK-801) and phencyclidine (PCP)
derivatives, have been reported to bind to NMDARs in an
activation-dependent manner [22, 23]. Thus, numerous
in vivo imaging agents have been developed to interact
with the PCP binding site, as this enables evaluation
of the distribution of functional NMDARs in the brain
under normal and pathological states. These agents include
PCP, MK-801, ketamine, memantine, and diarylguanidine
derivatives. [18F]1 (Figure 1), a PCP derivative with an
IC
50
of 61 nM for the ion channel site, showed an in vivo
distribution that was consistent with NMDAR expression.
Furthermore, coinjection of 1.7 𝜇mol/kg of the high-affinity
ion channel blocker, cis-2-hydroxymethyl-r-1-(N-piperidyl)-
1-(2-thienyl)cyclohexane (cis-HPTC), resulted in a reduction
in the regional cerebral distribution of [18F]1. However, this
tracer was unsuitable for use as an NMDAR PET radioligand
because of its high nonspecific binding in the brain [24]. A
3-[11C]cyano analog of MK-801 ([11C]MKC, Figure 1) has
been reported as a PET ligand with excellent affinity for the
channel blocker site (𝐾
𝑑
= 8.2 nM).This tracer showed highly
specific binding and heterogeneous in vitro distribution in rat
brain slices that was similar to the expression of NMDARs.
In PET studies, [11C]MKC showed a rapid and high uptake
into the brains of rhesus monkeys, with higher accumulation
in the frontal cortex than in the cerebellar cortex. However,
these distribution patterns correlated closely with regional
cerebral blood flow and blocking with NMDAR antagonists
did not affect the regional brain distribution of this tracer
[25]. PCP and MK-801 analogs showed high nonspecific
in vivo binding, probably due to their high lipophilicity.
Diarylguanidines have been identified as highly potent
NMDAR channel blockers, with less hydrophobicity than
PCP and MK-801. Therefore, several radiolabeled diarylgua-
nidine analogs have been reported as PET or SPECT ligands.
N-(1-naphthyl)-𝑁󸀠-(3-iodophenyl)-𝑁󸀠-methylguanidine
(CNS 1261, Figure 1) has been developed as a high-affinity
SPECT ligand for the ion channel site (𝐾
𝑖
= 4.2 nM) with
moderate lipophilicity (logD = 2.19). In ex vivo autoradio-
graphic studies, [125I]CNS 1261 showed 2.4–2.9-fold higher
uptake by the hippocampus than by the cerebellum in normal
rat brains. This accumulation pattern was consistent with the
pattern of NMDAR expression. In addition, investigation
of [125I]CNS 1261 binding in a mouse model of cerebral
ischemia revealed that [125I]CNS 1261 showed 2-fold higher
uptake by the caudate nucleus in the ischemic hemisphere,
as compared to the same region of the nonischemic
hemisphere (Figure 2). This suggested that [125I]CNS 1261
bound selectively to activated NMDARs [26]. Based on this
positive result, several clinical SPECT studies employing
[123I]CNS 1261 have been performed. In healthy volunteers,
no significant difference in the total distribution volume (𝑉
𝑇
)
was observed between the NMDAR-rich regions (striatum,
hippocampus, and frontal cortex) and the NMDAR-poor
cerebellum [27, 28]. Numerous reports have suggested
that hypofunction of NMDARs is associated with the
pathophysiology of schizophrenia [29, 30]. It is reported
that drug-free patients with schizophrenia showed reduced
binding of [123I]CNS 1261 in the left hippocampus relative
to the whole cortex, compared with healthy controls [31].
In contrast, a separate study demonstrated that 𝑉
𝑇
values
of [123I]CNS 1261 in drug-free or typical antipsychotic-
treated schizophrenia patients did not differ significantly
from those observed in the control group [32]. Therefore,
these reports did not provide evidence to support the
proposal that NMDARs could be imaged by SPECT using
[123I]CNS 1261. N-(2-chloro-5-thiomethylphenyl)-𝑁󸀠-(3-
[11C]methoxy-phenyl)-𝑁󸀠-methylguanidine [11C]GMOM
(Figure 1) is a 11C-labeled diarylguanidine derivative with a
high affinity for the ion channel site (𝐾
𝑖
= 5.2 nM). In PET
studies conducted in baboons, [11C]GMOM showed BBB
permeability. However, brain distribution of [11C]GMOM
was almost homogeneous and preadministration of
MK801 did not significantly change the regional 𝑉
𝑇
[33].
Another diarylguanidine derivative, N-(2-chloro-5-(methy-
lmercapto)phenyl)-𝑁󸀠-[11C]methylguanidine monohydroc-
hloride ([11C]CNS 5161, Figure 1), had excellent affinity
for the ion channel site (𝐾
𝑖
= 1.9 nM). [3H]CNS 5161
showed a heterogeneous in vivo distribution in rat brain
and a cortex/cerebellum ratio of 1.4. Pretreatment with
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Figure 2: Ex vivo autoradiograms of [125I]CNS 1261 in the caudate nucleus (white arrow) and cerebral cortex (black arrow) of rat brain
(a). Quantified regional isotope levels normalized to cerebellum (b). The animals were injected with [125I]CNS 1261 15min after permanent
occlusion of the middle cerebral artery (left hemisphere) and sacrificed 120min later [26].
NMDA increased the hippocampus/cerebellum ratio to
1.6–1.9, while MK801 reduced the ratios to close to 1.0 [34].
Clinical PET studies using [11C]CNS 5161 indicated that
the largest uptake occurred in the putamen and thalamus
and the lowest uptake was observed in the cerebellum, but
relatively low levels of radioactivity were detected in the
NMDAR-rich hippocampus [35]. Further investigations are
necessary in order to provide consistent evidence that these
diarylguanidines can be used as PET or SPECT radioligands
for the channel blocker binding site of theNMDAR. Recently,













































[11C]L-703,717: R = H
[11C]AcL703: R = Ac
[11C]3: R = Et
[11C]4: R = I
Figure 3: Chemical structure of imaging probes for glycine binding site of NMDARs.
[18F]GE-179 (Figure 1), a high-affinity channel blocker (𝐾
𝑖
=
2.4 nM) [36], was radiolabeled and used for PET imaging in
healthy human subjects. Although this tracer showed high
brain uptake, the𝑉
𝑇
of each region was correlated to cerebral
blood flow rather than the levels of NMDAR expression.
Further characterization of [18F]GE-179 may be necessary
with in vivo PET studies using NMDAR-activated models
[37].
2.2. Imaging Probes for the NMDAR Glycine Binding Site. A
number of antagonists of the NMDAR glycine binding site
have been developed as anticonvulsant and neuroprotective
drugs [38]. Several radiolabeled cyclic amino acid deri-
vatives, such as [11C]-3-[2-[(3-methoxyphenylamino) carbo-
nyl]ethenyl]-4,6-dichloroindole-2-carboxylic acid ([11C]
3MPICA, Figure 3) and [18F]2, have excellent binding
affinities for the glycine binding site (𝐾
𝑖
= 4.8 and 6.0 nM,
resp.). However, they showed poor in vivo BBB permeability
and had brain accumulation patterns that were inconsistent
with those of theNMDAR [39, 40]. Since the lowbrain uptake
of the cyclic amino acid derivatives was due to the highly
polar charged carboxylate group, 4-hydroxyquinolones
(4-HQs), which are carboxylic bioisosteres, have been
investigated as high-affinity antagonists of the glycine
binding site. 3-[3-(4-[11C]methoxybenzyl)phenyl]-4-hydr-
oxy-7-chloroquinolin-2(1H)-one ([11C]L-703,717, Figure 3)
has been developed as one of the most potent glycine site
antagonists with a 4-HQ backbone (IC
50
= 4.5 nM versus
[3H]L-689,560) [41, 42]. In vivo experiments in mice showed
poor initial brain uptake of [11C]L-703,717 {0.32−0.36
percent injected dose per gram of tissue (% ID/g) at 1min}
and high levels of radioactivity in the blood. Since warfarin
administration caused a dose-dependent enhancement of the
initial brain uptake of [11C]L-703,717, this tracer may have a
high affinity for plasma protein warfarin binding sites. The
accumulation of [11C]L-703,717 in the cerebrum was lower
than that observed in the cerebellum at 30min (0.20% ID/g
versus 0.65% ID/g).This distribution patternwas inconsistent
with that of NMDAR expression. It should be noted that
treatment with nonradioactive L-703,717 (2mg/kg) only led
to a significant reduction in the accumulation of [11C]L-
703,717 in the cerebellum [43]. In order to improve the
BBB permeability of [11C]L-703,717, an acetyl derivative
of L-703,717 ([11C]AcL703, Figure 3) was developed as a
prodrug radioligand. Initial brain uptake of [11C]AcL703 at
1min was 2-fold higher than that of [11C]L-703,717. In rat
brain tissues, approximately 80% of [11C]AcL703had been
metabolized to [11C]L-703,717 by 20min after injection.
In ex vivo studies, [11C]AcL703 showed higher uptake in
the cerebellum than in the cerebrum, consistent with the
findings using [11C]L-703,717 [44]. Although a clinical PET
study of [11C]AcL703 was performed in healthy volunteers,
cerebellar NMDARs could not be visualized by PET due to
poor BBB penetration [45]. Other radiolabeled 4-HQs (3
and 4, Figure 3) with lower lipophilicity than [11C]L-703,717
have been developed as high-affinity radioligands for the
glycine site (𝐾
𝑖
= 7.2 and 10.3 nM). However, [11C]3 and
[11C]4 did not exhibit a significant increase in brain uptake,
as compared with [11C]L-703,717 [46]. The 4-HQs are
acidic (p𝐾
𝑎
≦ 5) [42] and this may result in strong binding
affinity for serum albumin and low BBB penetration. Thus,
several amino 4-HQ derivatives with lower p𝐾
𝑎
values were
synthesized and evaluated as new PET radioligands for the
glycine site. Methylamino derivatives of 4-HQs, 5 and 6
(Figure 3), showed high affinity for the glycine site (𝐾
𝑖
=
11.7 nM and 11.8 nM, resp.). Although the amine derivatives
showed a much lower plasma protein binding ratio than
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the methoxy analogs, [11C]6 still displayed poor uptake into
the brain [47]. Further structure-activity relationship studies
are necessary to develop PET ligands for the glycine site
with significantly improved BBB penetration. Furthermore,
the brain distribution of imaging agents interacting with the
glycine site can be greatly influenced by endogenous agonists.
The NMDAR coagonists, glycine and d-serine, are present
in the brain at micromolar levels. Glycine is ubiquitously
distributed in the brain, while d-serine is predominantly
found in the forebrain [48, 49]. Levels of d-serine are
reportedly very low level in the cerebellum, because of the
high expression level of an enzyme (d-amino acid oxidase,
DAO) that can degrade d-serine [50]. Consistent with the
above reports, the [11C]L-703,717 signal in the cerebellum
was diminished in mutant ddY/DAO-mice, which have
high cerebellar d-serine levels (Figure 4). The refore, the
low accumulation of [11C]L-703,717 in forebrain regions
may reflect the strong inhibition caused by the high level
of endogenous d-serine. Similarly, the higher uptake of
[11C]L-703,717 in the cerebellum might be due to reduced
binding inhibition by d-serine [51].
2.3. Imaging Probes for the NR2B Negative Modulator Binding
Site. NMDARs containing the NR2B subunit play a key role
in various diseases, such as Parkinson’s disease, Alzheimer’s
disease, and neuropathic pain. NR2B negative modulators
have been developed for the treatment of these conditions
[17, 52]. Ligands targeting NR2B, including ifenprodil, are
thought to bind at the interlobe cleft of the NR2B subunit
[53]. CP-101,606 is a potent NMDAR antagonist that is
highly selective for NR2B subunit-containing receptors, with
𝐾
𝑑
values of 10 nM [54]. Because CP-101,606 was identified
as a potent NR2B negative modulator (𝐾
𝑖
= 10 nM), a
11C-labeled CP-101,606 derivative ([11C]7, Figure 5) was
developed as a PET ligand for the NR2B subunit [55]. In
vitro binding of [11C]7 in rat brain slices was extremely high
in the forebrain regions and very low in the cerebellum,
with excellent specific binding (Figures 6(a) and 6(b)). This
distribution pattern matched the NR2B subunit expression
pattern [56]. However, in vivo studies in mice and monkeys
demonstrated that this tracer showed homogeneous brain
distribution and no specific binding of [11C]7 was observed
(Figure 6(c)) [55]. A benzylpiperidine derivative, [11C]8
(Figure 5), has been developed as a selective high-affinity
PET ligand for NR2B-containing NMDARs (IC
50
= 5.3 nM).
An in vivo study in rats showed poor brain uptake of [11C]8
and a localization that was inconsistent with the NR2B
expression pattern [57]. [11C]EMD-95885 (Figure 5), a
benzylpiperidine derivative with a high affinity for NR2B
(IC
50
= 3.9 nM), has been synthesized and evaluated. In
vivo experiments in rats showed 59-fold higher brain uptake
of [11C]EMD-95885 than of [11C]8. Although [11C]EMD-
95885 displayed homogeneous binding in brain tissues,
a substantial reduction in brain uptake of [11C]EMD-
95885 was observed in the presence of nonradioactive 8
or ifenprodil, suggesting that some specific binding may
occur in the brain. However, these blocking effects were
observed in both NR2B-rich and NR2B-poor regions
[58]. The benzimidazole derivatives, 9 and 10 (Figure 5),
have been identified as having high affinity for the NR2B
subunit, with 𝐾
𝑖
values of 7.3 nM and 5.8 nM, respectively.
Both [125I]9 and [125I]10 showed localizations consistent with
NR2B subunit expression in rat brain slices. In vivo studies
in mice found moderate brain uptake of [125I]9 and [125I]10
and distribution that was inconsistent with known NR2B
expression patterns. However, treatment with nonradioactive
9 or the NR2B ligand, [(±)-(𝑅∗, 𝑆∗)]-a-(4-hydroxyphenyl)-
𝛽-methyl-4-(phenylmethyl)-1-piperidine propanol (Ro
25–6981), caused 34% and 59% reduction in the brain/blood
ratio of [125I]9, respectively. This tracer may therefore
show partially specific binding to the NR2B subunit in vivo
[59]. Further structural modification of 9 may contribute
to the development of more promising imaging probes
for the NR2B subunit. [2-(3,4-Dihydro-1H-isoquinolin-2-
yl)-pyridin-4-yl]–[11C]dimethylamine ([11C]Ro-647312,
Figure 5) has been evaluated as a member of a different
class of PET ligands with high affinity for the NR2B
subunit (𝐾
𝑖
= 8.0 nM). However, in vivo biodistribution of
[11C]Ro-647312 was almost homogeneous in the brain [60].
Several benzylamidines, such as [11C]11 (Figure 5), have been
developed as high-affinity PET ligands forNR2B (𝐾
𝑖
= 5.7 nM
for 11). In vitro, [11C]11 showed excellent specific binding and
a similar localization to that of NR2B. However, [11C]11 is an
unsuitable imaging agent due to metabolic instability [61].
(3S,4R)-4-Methylbenzyl 3-fluoro-4-((pyrimidin-2-ylamino)
methyl) piperidine-1-carboxylate (MK-0657) was developed
as a highly potent NR2B antagonist (IC
50
= 3.6 nM) for the
treatment of neuropathic pain, Parkinson’s disease, andmajor
depression [17, 62]. Two radiofluorinated diastereoisomers
of MK-0657 ([18F]trans-MK-0657 and [18F]cis-MK-0657,
Figure 5) exhibited a localization pattern consistent with
that of NR2B expression and very high specific binding for
the NR2B modulator binding site. However, no further in
vivo evaluations of these potential imaging agents have been
reported [63].
3. mGluRs
mGluRs are widely expressed though the CNS and their
activation leads to various effects on neuronal synaptic
transmission via regulation of ion channels and signaling
proteins. Dysregulation of mGluRs has been observed in
various conditions affecting the CNS, such as anxiety [64],
depression [65], Alzheimer’s disease [66], schizophrenia
[67], Parkinson’s disease [68], and epilepsy [69]. Positive
and negative modulators of mGluRs have therefore been
developed for the treatment of these neurological diseases.
Nuclear medicine imaging of mGluRs can be used for the
investigation of a range of diseases, in addition to monitoring
receptor occupancy by therapeutic agents. Thus, a consid-
erable number of PET imaging probes for mGluRs have
been reported. PET ligands for group I mGluRs (mGluR1
and 5) have been developed extensively and several of these
have been confirmed as promising ligands in clinical studies.
Recently, potential PET probes for mGluR2 (group II) have
also been reported and have proceeded to phase I studies. No





Figure 4: Ex vivo autoradiograms of [11C]L-703,717 in the brain of normal ddY/DAO+ (a) and mutant ddY/DAO-mice (b) 30min after
















































[125I]9: R1 = OH, R2







Figure 5: Chemical structure of imaging probes for NR2B negative modulator binding site of NMDARs.
clinically useful PET ligands for group III mGluRs have been
published, due to a lack of selectivity over other mGluRs.
3.1. Imaging Probes for Group I mGluRs
3.1.1. Physiology of Group I mGluRs. Group I mGluRs
(mGluR1 and mGluR5) are predominantly expressed in the
postsynaptic neuron. Their activation leads to increased
neuronal excitability and they are involved in modulation
of synaptic plasticity at glutamatergic synapses. They are
coupled to Gq/G11 and upregulate inositol triphosphate
and diacylglycerol levels via phospholipase C activation,
triggering calcium mobilization, and activation of protein
kinase C (PKC). In addition, group I mGluRs have been
reported to be implicated in the mitogen-activated pro-
tein kinase (MAPK)/extracellular signal-regulated kin+ase
(ERK) and mammalian target of rapamycin (mTOR)/p70
S6 kinase pathways, which can regulate synaptic plasticity
[70]. Complementary expression of mGluR1 and mGluR5
has been observed in the rodent brain. mGluR1 are found
extensively throughout the brain, but are highly expressed in
the cerebellar cortex, hippocampus, and thalamus. mGluR5
expression has been observed in the cerebral cortex, hip-
pocampus, accessory olfactory bulbs, and nucleus accumbens
[71]. mGluR1 antagonists have shown promising anxiolytic
and antidepressant effects, whereas positive modulators of
mGluR1 have been reported to be useful for the treatment
of schizophrenia. Negative modulators of mGluR5 can be
effective in the treatment of anxiety, fragile X syndrome,
chronic pain, and depression [72]. In contrast, positive
modulators of this receptor have potential for the treatment
of schizophrenia [73].















































Figure 6: In vitro autoradiogram of [11C]7 (a) and quantified values of the autoradiogram in frontal cortex (FTX), hippocampus (HIP),
striatum (STR), thalamus (THA), and cerebellum (CB) (b). Nonspecific binding was determined in the presence of (+) CP-101,606 (10𝜇M).
(c) Time radioactivity curves in the monkey brain after administration of [11C]7. Nonradioactive 7 (2mg/kg) was coinjected with [11C]7 into
the same monkey [55].
3.1.2. Development of Imaging Probes for mGluR1. (3-Ethyl-2-
[11C]methyl-6-quinolinyl)(cis-4-methoxycyclohexyl)metha-
none ([11C]JNJ-16567083, Figure 7) has been developed as a
high-affinity, selective mGluR1 ligand (𝐾
𝑖
= 4.41 nM for rat
mGluR1, 13.3 nM for human mGluR1) [74]. Ex vivo studies
using this ligand showed good brain uptake and a localization
pattern consistent with mGluR1 expression. In addition, over
80% of the accumulation of [11C]JNJ-16567083 in the
cerebellum was blocked by selective mGluR1 antagonists,
while treatmentwith a selectivemGluR5 antagonist produced
no marked inhibition of its binding, indicating selectivity
for mGluR1. In PET studies, it showed high specific binding
in regions expressing mGluR1, indicating that [11C]JNJ-
16567083 is bound to mGluR1 in the living rat brain [74].
An 18F-labeled JNJ-16567083 derivative ([18F]12, Figure 7)
was also reported to have a high affinity for mGluR1 (𝐾
𝑖
=
1.77 nM for rat mGluR1 and 24.4 nM for human mGluR1).
The in vivo localization of [18F]12 in rats was similar to that
of [11C]JNJ-16567083. The in vivo accumulation of [18F]12 in
the cerebellum was inhibited by pretreatment with a selective
mGluR1 antagonist, but not by an mGluR2 antagonist
(LY341495) or an mGluR5 antagonist (MPEP), indicating
selectivity for mGluR1 in the living rat brain. However, PET
studies in baboons found that [11C]JNJ-16567083 and [18F]12
produced low brain signals, probably due to a lower receptor
density in baboon brain than in rat brain [75]. These results
suggested that less lipophilic and/or higher affinity mGluR1




oxamide (YM-202074, Figure 7) has been reported as a














































[11C]JNJ-16567083: R = 11CH3
[11C]12: R = 18F
[11C]ITMM: R = O11CH3
[11C]ITDM: R = 11CH3
[18F]FITM: R = 18F









Figure 8: Sagittal PET images (0–60min) of [11C]ITMM in wild-type (a) and mGluR1 knockout (b) mice brains [83].
high-affinity, selective mGluR1 ligand (𝐾
𝑖
= 4.8 nM for rat
mGluR1) with lower lipophilicity than JNJ-16567083 (logD =
2.7 versus 3.38). Although [11C]YM-202074 showed in vitro
accumulation consistent with mGluR1 expression in the rat
brain, PET studies in rats using this ligand demonstrated
a low brain uptake and localization that was inconsistent
with mGluR1-rich regions. These findings may be attributed
to rapid ligand metabolism and the subsequent influx
of radiometabolites into the brain [76]. 1-(2-Fluoro-3-
pyridyl)-4-(2-propyl-1-oxoisoindoline-5-yl)-5-methyl-1H-
1,2,3-triazole (MK-1312, Figure 7) has been developed as a
potent mGluR1 ligand (IC
50
= 4.3 nM for human mGluR1),
with high selectivity and moderate lipophilicity (logP =
2.3). [18F]MK-1312 displayed similar in vitro localization to
that of mGluR1 and highly selective binding. PET studies of
this ligand in rhesus monkeys demonstrated rapid uptake
kinetics, with no significant defluorination in brain. In
addition, binding was inhibited by the mGluR1 antagonist,
MK-5435, in a dose-dependent manner [77]. Although these
results indicated that [18F]MK-1312 may be a promising PET
ligand for mGluR1, no further clinical studies have been
reported to date. 1-(2-Fluoro-3-pyridyl)-4-(2-isopropyl-
1-oxoisoindoline-5-yl)-5-methyl-1H-1,2,3-triazole (FPIT,
Figure 7), an MK-1312 derivative, has been reported as a
selective mGluR1 ligand with an IC
50
of 5.4 nM for human
mGluR1 [77]. [18F]FPIT showed similar in vitro distribution
to mGluR1 in both rat and monkey brains. In addition, its
accumulation was selectively blocked by an mGluR1 ligand,
indicating excellent specific binding (95%). PET/magnetic
resonance imaging (MRI) studies of this ligand in rats and
monkeys demonstrated a distribution that was consistent
with that observed in vitro. Brain accumulation of [18F]FPIT
was significantly inhibited by nonradioactive FPIT and by
the mGluR1-selective ligand JNJ-16259865 [78]. Although
[18F]FPIT has been demonstrated to be a prospective PET
probe for mGluR1, further clinical studies have not yet been
performed, probably due to the slow pharmacokinetics,
and the influx of small levels of radiometabolites into the
brain. 4-Fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-
1,3-thiazol-2-yl]-N-methylbenzamide (FITM, Figure 7) was
developed as a potent mGluR1 antagonist (IC
50
= 5.1 nM)
with high selectivity [79] and low lipophilicity (logD = 1.46)





Figure 9: PET/MRI images of [11C]ITMM (40–60min) obtained from 5 healthy human subjects. Upper: MR image and lower: averaged
[11C]ITMM PET image [85].
[80]. In vitro and ex vivo binding of [18F]FITM matched
the distribution of mGluR1, with high specific binding in
mGluR1-rich regions [80]. [18F]FITM showed high brain
uptake (>7% ID/g in mice) and metabolic stability, with
95% intact [18F]FITM detected in the rat brain 120min
after injection. Rat and monkey PET studies demonstrated
a radioactive signal distribution consistent with that of the
mGluR1, with very high specific binding. Kinetic analysis
showed that the calculated 𝑉
𝑇
values of [18F]FITM were
also consistent with the localization of mGluR1 [81]. PET
studies of [18F]FITM in rat brain that included blocking
experiments determined 𝐵max and 𝐾𝑑 values in several
brain regions with moderate mGluR1 expression, such as
the thalamus, hippocampus, striatum, and cingulate cortex,
consistent with the density of mGluR1 in these regions.
However, because of its relatively slow kinetics, 𝐵max and 𝐾𝑑
values of [18F]FITM could not be measured in the mGluR1-
rich cerebellum [82]. Although these findings have shown
that [18F]FITM is a prospective PET radiotracer for mGluR1,
no further clinical PET studies have been reported in the
literature. It is reported that [18F]FITM could be prepared in
poor radiochemical yields (14 ± 3%), probably due to using
the 4-nitrobenzamide precursor [80]. It is suggested that
optimized methods for radiosynthesis of [18F]FITM should
be developed. N-[4-[6-(Isopropylamino)pyrimidin-4-yl]-
1,3-thiazol-2-yl]-4-methoxy-N-methylbenzamide (ITMM,
Figure 7) has been reported to be a highly potent and selective
PET probe for mGluR1, with a 𝐾
𝑖
value of 12.6 nM (rat brain
homogenate) and a logD value of 2.57. In vitro binding of
[11C]ITMM was consistent with mGluR1 distribution, with
high specific binding inmGluR1-rich regions. A PET study in
rats found that [11C]ITMMdisplayed high brain uptake, with
the highest uptake (in the cerebellum) being over 3.0 of the
SUV (standardized uptake value). The in vivo distribution
of [11C]ITMM was consistent with the in vitro data. The
heterogeneous localization of [11C]ITMM was abolished
by treatment with nonradioactive ITMM and an mGluR1-
selective ligand. In addition, a PET study of [11C]ITMM in
the mGluR1 knockout mouse demonstrated quite low uptake
and homogeneous distribution of radioactivity in the brain
(Figure 8) [83]. Furthermore, [11C]ITMM showed reduced
accumulation in the ischemic brain and treatment with
the neuroprotective agent, minocycline, which may inhibit
mGluR1 activation, abolished this decrease of mGluR1 in the
brain [84]. Because [11C]ITMM has been demonstrated to
be a promising PET tracer for mGluR1, the first human PET
studies have been performed. [11C]ITMM uptake increased
gradually in the cerebellar cortex and 𝑉
𝑇
in this brain region
was 2.61, while 𝑉
𝑇
was 0.53 in the mGluR1-poor pons.
The rank order of [11C]ITMM uptake was consistent with
mGluR1 expression levels in the human brain (Figure 9).
Because [11C]ITMM showed relatively low uptake in the
brain regions with a modest expression of mGluR1, such
as the thalamus, hippocampus, and cerebral cortex, the
[11C]ITMM signal in regions outside the cerebellum could
be difficult to assess and this would make it hard to examine
localization changes in these regions [85]. Nevertheless,
[11C]ITMMcould be used to evaluate alterations in cerebellar
mGluR1 under pathological conditions. Further clinical
studies may be needed to assess the usefulness of [11C]ITMM
as a PET ligand for quantification of mGluR1.
N-[4-[6-(Isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-
yl]-N-methyl-4-11C-methylbenzamide ([11C]ITDM, Figure 7),
an analog of ITMM, also has high affinity for mGluR1 (𝐾
𝑖
= 13.6 nM) and moderate lipophilicity (logD = 1.74). PET
studies of [11C]ITDM in the monkey brain showed localiza-
tion consistent with knownmGluR1 expression, fast kinetics,
and a very low level of binding in themGluR1-poor pons [86].
After detailed kinetic studies, [11C]ITDM was considered
superior to [11C]ITMM because of its higher regional
𝑉
𝑇
values in the monkey brain [87]. Global reduction of
[11C]ITDM binding was observed in the mGluR1-expressing
brain regions of the R6/2 mouse model of Huntington’s
disease. The change in the radioactive signal correlated with
the expression of mGluR1 in the brains of these R6/2 mice
[88]. Thus, [11C]ITDM has been confirmed as a promising
PET ligand for monitoring changes in mGluR1 availability
in the brain. To our knowledge, clinical PET studies with
[11C]ITDM have not yet been published. [18F]4-Fluoro-N-
methyl-N-(4-(6-(methylamino)pyrimidin-4-yl)thiazol-2-yl)
benzamide ([18F]FIMX, Figure 7) has been shown to have
a high affinity for mGluR1 (IC
50
= 1.8 nM) with high
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selectivity against a wide range of other human receptors
[79, 89]. [18F]FIMX was successfully synthesized by the
radiofluorination of the diaryliodonium salts precursor.
FIMX has moderate lipophilicity, with a logD value
of 2.25. PET studies of [18F]FIMX in rhesus monkey
demonstrated high BBB permeability and maximal uptake
in the mGluR1-rich cerebellum (SUV = 5.3 at 12min). The
distribution of radioactivity in the brain matched mGluR1
expression, and accumulation was abolished by treatment
with nonradioactive FIMX or the mGluR1-selective ligand
JNJ-1625968553 (3mg/kg, resp.). In contrast, an mGluR5-
selective ligand (MTEP) did not affect [18F]FIMX binding
in the monkey brain [89]. Apparently, [18F]FIMX is a
prospective PET radioligand for imaging of mGluR1.
Recently, an initial clinical PET imaging study using 18F-
FIMX was performed. The mGluR1-rich cerebellum had the
highest uptake (SUV; 1.8 at 120min), whereas mGluR1-poor
regions ranged from SUV values of 0.3–1 at 120min [90].
PET imaging of patients with a range of CNS disorders using
[18F]FITM, [11C]ITMM, [11C]ITDM, and [18F]FIMX could
help to elucidate the relationship between these disorders
and mGluR1.
3.1.3. Development of Imaging Probes for mGluR5. Several
diaryl alkyne derivatives have been reported as high-affinity,
selective mGluR5 antagonists that could be used as in vivo
imaging probes. 3-Fluoro-5-(2-pyridinylethynyl) benzoni-
trile (FPEB, Figure 10) has been reported to have an excellent
affinity for mGluR5, with a 𝐾
𝑖
value of 0.2 nM (rat brain
cortex) and a moderate logP value of 2.8. Autoradiography
of rhesus monkey brain demonstrated high accumulation in
mGluR5-rich regions, such as the cortex, caudate, putamen,
amygdala, hippocampus, andmost thalamic nuclei, and a low
signal in the mGluR5-poor cerebellar layers. In addition, the
heterogeneous binding of [18F]FPEB was abolished in the
presence of the mGluR5-selective ligand, MPEP, indicating
that the radiotracer bound specifically to mGluR5 in vitro
[91]. PET studies of [18F]FPEB in rhesus monkey and rat
showed similar localization to mGluR5 and displacement
by mGluR5 ligands (Figure 11) [91, 92]. Building on these
promising preclinical studies of [18F]FPEB, an initial clin-
ical PET study was performed to assess the usefulness of
this radiotracer for PET imaging of mGluR5. The regional
brain distribution of [18F]FPEB in the healthy adult brain
matched the known expression of mGluR5 and showed high
reproducibility, suggesting that [18F]FPEB is a suitable PET
radioligand for mGluR5 in the human brain [93].
3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-
O-11C-methyl-oxime ([11C]-ABP688, Figure 10) has been
reported as a highly selective and potent radiotracer for the
mGluR5 allosteric site, with a 𝐾
𝑑
value of 1.7 nM in rat brain
homogenates. Ex vivo autoradiography of [11C]ABP688
demonstrated high accumulation of this radiotracer in
mGluR5-rich brain regions, such as the cingulate cortex,
striatum, and hippocampus. Treatment with M-MPEP
(1mg/kg), an mGluR5-selective antagonist, abolished the
heterogeneous localization of [11C]ABP688. PET studies
using [11C]ABP688 in normal rats demonstrated a similar
distribution to that observed in ex vivo experiments
(Figure 12). In addition, accumulation of this radiotracer was
almost homogeneous in mGluR5-knockout mice, indicating
that [11C]ABP688 was highly specific for mGluR5 in the
living brain [94]. A clinical PET study of [11C]ABP688 in
human brain demonstrated high accumulation in mGluR5-
rich brain regions but low levels in themGluR5-poor regions,
consistent with the results of rat PET studies. Its specific
distribution volume in the brain regions ranged from 5.45
(anterior cingulate) to 1.91 (cerebellum), and the rank order
of these values was consistent with the known mGluR5
density. These results suggested that [11C]ABP688 could be
used for PET quantification of mGluR5 in the human brain
[95]. It has also been reported that [11C]ABP688 can be
used for monitoring mGluR5 drug occupancy. AZD2066, a
highly potent mGluR5-selective ligand, dose-dependently
displaced [11C]ABP688 binding in the human brain
(Figure 13). In this study, the dose of AZD2066 required
to produce 50% mGluR5 occupancy was estimated to be
13.5mg [96]. On the other hand, there are two geometrical
isomers of [11C]ABP688 and the E-isomer has a much higher
binding affinity for mGluR5 than the Z-isomer (𝐾
𝑑
= 5.7 nM
versus 140 nM). In a rat PET study of [11C]ABP688, the
E-isomer showed high brain uptake and distribution that
was consistent with mGluR5 expression. In contrast, the
Z-isomer showed low brain retention and homogeneous
binding throughout the brain [97]. Although [11C]ABP688
could be synthesized with an E-isomer to Z-isomer ratio of >
10 : 1 [94], it has been suggested that E-[11C]ABP688 should
be used for reproducible imaging of mGlu5 receptors in
clinical studies. 3-Fluoro-5-[2-[2-([18F]fluoromethyl)thiazol-
4-yl]ethynyl]benzonitrile ([18F]SP203, Figure 10) has been
developed as a negative allosteric modulator with excellent
affinity (40 pM) for mGluR5. PET studies using [18F]SP203
demonstrated high uptake in mGluR5-rich regions and the
signal was greatly diminished by treatment with themGluR5-
selective ligand MPEP (5mg/kg) [98]. One disadvantage of
[18F]SP203 is the ease of its defluorination by glutathione
S-transferase in the rat brain [99]. However, because primates
have much lower levels of glutathione S-transferase [100],
initial PET studies were conducted with [18F]SP203 in
healthy human subjects. PET images showed high brain
uptake of [18F]SP203 (Figure 14) with little defluorination
and brain uptake could be calculated as 𝑉
𝑇
in humans.
[18F]SP203 had high BBB permeability (% SUV; ∼580) and
the rank order of 𝑉
𝑇
values in the brain regions was as
follows: neocortex (20–26) > thalamus (15) ≒ cerebellum
(14), consistent with the levels of mGluR5 in the human
brain [101]. Therefore, despite the issue of defluorination,
18F-SP203 can be used for quantification of mGluR5 by PET.
3.1.4. mGluR5-Selective PET Imaging in Diseases. Cocaine
exposure has been reported to reduce mGluR5 expression
in the rodent brain [102]. Clinical PET studies were con-
ducted with [11C]ABP688 in cocaine-addicted participants,
in comparison with healthy control subjects. [11C]ABP688
binding in the striatum was reduced by approximately 20%



















Figure 11: PET images of [18F]FPEB (20–25min) in rat brain without drug treatment (a), treatment of mGluR5-selective ligand MTEP
treatment (10mg/kg) (b), and treatment of mGluR1-selective YM-298198 (10mg/kg) [92].
in cocaine-addicted participants [103]. Another clinical PET
study with [11C]ABP688 demonstrated that mGluR5 avail-
ability in cocaine-dependent subjects was inversely propor-
tional to the duration of cocaine abstinence [104]. These
studies indicated that distribution of mGluR5 was decreased
in the striatum of the living brain in cocaine-abstinent
individuals, information that could inform novel strategies
for the control of cocaine addiction via mGluR5. Preclinical
studies have demonstrated that mGluR5 antagonists potently
reduced self-administration of nicotine [105, 106]. In a PET
study, a significant reduction in [11C]ABP688 binding was
observed in the graymatter of smokers (Figure 15), indicating
that mGluR5 could be a potential target for the treatment of
nicotine dependence [107]. mGluR5 have been suggested to
be involved in the pathophysiology of epilepsy [108, 109]. PET
studies using [11C]ABP688 revealed lower levels of mGluR5
binding in the hippocampus and amygdala in rat models of
chronic epilepsy, as compared to a control group. Therefore,
PET imaging of mGluR5 in the temporal and spatial regions
could detect dysregulated glutamatergic networks during
epileptogenesis [110]. mGluR5 may also be linked to the
pathophysiology ofmajor depression [65]. Clinical PET stud-
ies using [11C]ABP688 showed reduced mGluR5 binding in
the cortical regions, thalamus, and hippocampus of patients
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Figure 12: PET images of [11C]ABP688 (0–30min) in control rats (a) and an mGluR5-selective ligand M-MPEP (1.0mg/kg) treated rat [94].












Figure 13: PET/MR images (0–63min) showing the effect of AZD2066 on binding of [11C]ABP688 [96].
with depression. Furthermore, mGluR5 availability in the
hippocampus decreased with the increased severity of this
disease, suggesting that changes in the availability of mGluR5
may provide a potential biomarker for the diagnosis of
depression [111].
3.2. Imaging Probes for Groups II and III mGluRs
3.2.1. Physiology of Groups II and III mGluRs. Groups II
(mGluR2 and mGluR3) and III (mGluR4, mGluR6, mGluR7,
and mGluR8) mGluRs are primarily localized within presy-
naptic regions and involved in the inhibition of neurotrans-
mitter release [70]. Groups II and III mGluRs are coupled
to Gi/Go and downregulate cAMP levels via inhibition of
adenylate cyclase. These events activate the MAPK and
phosphatidylinositol 3-kinase (PI3) pathways, which reg-
ulate synaptic transmission. mGluR2 has been predomi-
nantly observed in the cerebellar cortex and olfactory bulb,
while mGluR3 has been found widely throughout the brain.
mGluR4 is predominantly expressed in the cerebellum. The
expression of mGluR6 is restricted to the retina, whereas
mGluR7 has a widespread distribution in the brain. mGluR8
is mainly expressed in the olfactory bulbs, olfactory nucleus,
piriform cortex, entorhinal cortex, and medulla oblongata
[71]. Agonists of group II mGluRs may be useful in the treat-
ment of anxiety disorders and schizophrenia [73]. mGluR2/3
are involved in the pathophysiology of schizophrenia [112].
Group III mGluRs are attractive targets for the treatment



















































Figure 16: Chemical structure of imaging probes for groups II and III mGluRs.
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of Parkinson’s disease [113]. mGluR8 is implicated in drug
addiction mechanisms [114].
3.2.2. Development of Imaging Probes for Group II mGluRs.
8-Chloro-3-(cyclopropylmethyl)-7-[4-(3,6-difluoro-2-
methoxyphenyl)-1-piperidinyl]-1,2,4-triazolo[4,3-a]pyridine
([11C]JNJ42491293, Figure 16) has been reported to act as
a potent positive allosteric modulator for mGluR2, with
an IC
50
of 9.2 nM for the human mGluR2 and a high
selectivity against other mGluRs. In vivo biodistribution
and PET studies in rats demonstrated a high brain
uptake of [11C]JNJ42491293, with a signal matching
the known distribution of mGluR2 that was displaced by
JNJ42153605, a selective mGluR2 agonist, in all brain regions.
[11C]JNJ42491293 may be a promising PET radiotracer for
the mGluR2 allosteric binding site [115]. PET studies using
[11C]JNJ42491293 in healthy male subjects demonstrated
high brain uptake, which reached a maximum 30min after
treatment. Considerable [11C]JNJ42491293 distribution was
observed in the striatum and cerebellum, consistent with
known mGluR2 expression patterns. [11C]JNJ42491293 has
been demonstrated to be a prospective PET radioligand for
monitoring mGluR2 availability in the human brain [116].
3.2.3. Development of Imaging Probes for Group III mGluRs.
N-(Chloro-3-methoxyphenyl)-2-picolinamide (ML128,
Figure 16) has been developed as a positive allosteric
modulator ofmGluR4with an EC
50
of 110 nM for ratmGluR4
[117]. [11C]ML128 has been synthesized and evaluated as
a PET imaging probe for mGluR4. In rat PET studies,
[11C]ML128 showed high BBB penetration and localization
to the hippocampus, striatum, thalamus, olfactory bulb, and
cerebellum, consistent with the distribution of mGluR4.
Treatment with anmGluR4modulator led to some reduction
(22–28%) in [11C]ML128 binding in the brain. Because this
radiotracer exhibited fast washout within 20min throughout
the brain, structural modification will be necessary to
provide useful in vivo imaging probes for mGluR4 [118].
MMPIP (6-(4-methoxyphenyl-5-methyl-3-pyridin-4-
ylisozazolo[4,5-c]pyridine-4(5H)-one)) is an allosteric
mGluR7 antagonist with a 𝐾
𝑏
of 30 nM [119]. [11C]MMPIP
(Figure 16) has been synthesized and evaluated as a PET
radioligand for mGluR7. Although [11C]MMPIP showed
specific in vitro binding in rat brain, PET studies of this
radioligand in rats demonstrated low brain uptake and no
specific localization to sites of mGluR7 expression.
4. Conclusion and Perspectives
Despite considerable efforts, no radioligands are currently
available for human in vivo PET or SPECT imaging of
NMDARs. There are three potential target sites for imaging
agents; the channel blocker site, the glycine site, and theNR2B
negative modulator site. [123/125I]CNS 1261 is a potential
imaging agent acting at the channel blocker site. However,
this ligand requires further research to address its input func-
tion alteration in pathological state metabolic instability and
potentially nonspecific binding.There are no radioligands for
glycine site or the NR2B negative modulator site that have
shown enough promise to warrant clinical studies. Although
several ligands showed localization patterns consistent with
NMDAR expression and high specific binding in vitro, they
did not show these characteristics in vivo. This discrepancy
might be due to the dynamic properties of NMDARs. It
is known that NMDAR structure is altered by binding of
endogenous or exogenous ligands [1]. Importantly, the num-
ber of NMDARs on the cell surface is changed by tyrosine
phosphorylation, cysteine palmitoylation of the NMDAR C-
terminus, and by an alteration in subunit composition [120–
122]. In addition to developing novel classes of imaging
probes for NMDARs, further in vivo imaging studies of
NMDAR models should be performed to clarify the discrep-
ancies between the findings of in vitro and in vivo studies.
In contrast to the situation with NMDARs, several
promising PET probes for mGluRs have been developed suc-
cessfully. PET radioligands for mGluR1, such as [18F]FITM,
[11C]ITMM, [11C]ITDM, and [18F]FIMX, have proved useful
in clinical PET studies. PET imaging studies of mGluR5
with selective radiotracers ([18F]FPEB, [18F]SP203, and
[11C]ABP688) have enabled evaluation of mGluR5 avail-
ability in relevant disease states. [11C]JNJ42491293 has been
developed as a clinically useful prospective PET probe for
mGluR2. Further PET investigations of patients with various
mGluR-related diseases could make it possible to resolve the
roles of mGluRs in these disorders, monitor mGluR activity,
and quantify mGluR occupancy by therapeutic agents. As no
clinically useful PET ligands for group III mGluRs have yet
been identified, continued efforts should be made to develop
high-affinity and selective ligands for these receptors.
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[61] E. Årstad, S. Platzer, A. Berthele et al., “Towards NR2B receptor
selective imaging agents for PET-synthesis and evaluation
of N-[11C]-(2-methoxy)benzyl (E)-styrene-, 2-naphthyl- and
4-trifluoromethoxyphenylamidine,” Bioorganic and Medicinal
Chemistry, vol. 14, no. 18, pp. 6307–6313, 2006.
[62] C. Addy, C. Assaid, D. Hreniuk et al., “Single-dose admin-
istration of MK-0657, an NR2B-selective NMDA antagonist,
does not result in clinically meaningful improvement in motor
function in patients withmoderate Parkinson’s disease,” Journal
of Clinical Pharmacology, vol. 49, no. 7, pp. 856–864, 2009.
[63] R. Koudih, G. Gilbert, M. Dhilly et al., “Synthesis and in
vitro characterization of trans- and cis-[18F]-4-methylbenzyl
4-[(pyrimidin-2-ylamino)methyl]-3- fluoropiperidine-1-
carboxylates as new potential PET radiotracer candidates for
the NR2B subtype N-methyl-d-aspartate receptor,” European
Journal of Medicinal Chemistry, vol. 53, pp. 408–415, 2012.
[64] N. Pitsikas, “The metabotropic glutamate receptors: potential
drug targets for the treatment of anxiety disorders?” European
Journal of Pharmacology, vol. 723, no. 1, pp. 181–184, 2014.
The Scientific World Journal 17
[65] S. Chaki, Y. Ago, A. Palucha-Paniewiera, F. Matrisciano, and A.
Pilc, “MGlu2/3 andmGlu5 receptors: potential targets for novel
antidepressants,” Neuropharmacology, vol. 66, pp. 40–52, 2013.
[66] H.-G. Lee, X. Zhu, M. J. O’Neill et al., “The role of metabotropic
glutamate receptors in Alzheimer’s disease,” Acta Neurobiolo-
giae Experimentalis, vol. 64, no. 1, pp. 89–98, 2004.
[67] P. N. Vinson and P. J. Conn, “Metabotropic glutamate receptors
as therapeutic targets for schizophrenia,” Neuropharmacology,
vol. 62, no. 3, pp. 1461–1472, 2012.
[68] F. Gasparini, T. Di Paolo, and B. Gomez-Mancilla, “Meta-
botropic glutamate receptors for parkinson’s disease therapy,”
Parkinson’s Disease, vol. 2013, Article ID 196028, 11 pages, 2013.
[69] R. T. Ngomba, I. Santolini, T. E. Salt et al., “Metabotropic
glutamate receptors in the thalamocortical network: Strategic
targets for the treatment of absence epilepsy,” Epilepsia, vol. 52,
no. 7, pp. 1211–1222, 2011.
[70] F. Nicoletti, J. Bockaert, G. L. Collingridge et al., “Metabotropic
glutamate receptors: from the workbench to the bedside,”
Neuropharmacology, vol. 60, no. 7-8, pp. 1017–1041, 2011.
[71] F. Ferraguti and R. Shigemoto, “Metabotropic glutamate recep-
tors,”Cell and Tissue Research, vol. 326, no. 2, pp. 483–504, 2006.
[72] A. Slassi, M. Isaac, L. Edwards et al., “Recent advances in non-
competitive mGlu5 receptor antogonists and their potential
therapeutic applications,” Current Topics in Medicinal Chem-
istry, vol. 5, no. 9, pp. 897–911, 2005.
[73] P. J. Conn, C. W. Lindsley, and C. K. Jones, “Activation of
metabotropic glutamate receptors as a novel approach for
the treatment of schizophrenia,” Trends in Pharmacological
Sciences, vol. 30, no. 1, pp. 25–31, 2009.
[74] Y. Huang, R. Narendran, F. Bischoff et al., “A positron
emission tomography radioligand for the in vivo labeling of
metabotropic glutamate 1 receptor: (3-Ethyl-2-[11C]methyl-
6- quinolinyl)(cis-4-methoxycyclohexyl)methanone,” Journal
of Medicinal Chemistry, vol. 48, no. 16, pp. 5096–5099, 2005.
[75] Y. Huang, R. Narendran, F. Bischoff et al., “Synthesis and
characterization of two pet radioligands for the metabotropic
glutamate 1 (mGlu1) receptor,” Synapse, vol. 66, no. 12, pp. 1002–
1014, 2012.
[76] K. Yanamoto, F. Konno, C. Odawara et al., “Radiosynthesis and
evaluation of [11C]YM-202074 as a PET ligand for imaging the
metabotropic glutamate receptor type 1,” Nuclear Medicine and
Biology, vol. 37, no. 5, pp. 615–624, 2010.
[77] E. D. Hostetler, W. Eng, A. D. Joshi et al., “Synthesis, character-
ization, and monkey PET studies of [18F]MK-1312, a PET tracer
for quantification of mGluR1 receptor occupancy byMK-5435,”
Synapse, vol. 65, no. 2, pp. 125–135, 2011.
[78] M. Fujinaga, J. Maeda, J. Yui et al., “Characterization of 1-
(2-[18F]fluoro-3-pyridyl)-4-(2-isopropyl- 1-oxo- isoindoline-5-
yl)-5-methyl-1H-1,2,3-triazole, a PET ligand for imaging the
metabotropic glutamate receptor type 1 in rat and monkey
brains,” Journal of Neurochemistry, vol. 121, no. 1, pp. 115–124,
2012.
[79] A. Satoh, Y. Nagatomi, Y. Hirata et al., “Discovery and in
vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropy-
lamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide
as novel class of an orally active metabotropic glutamate
receptor 1 (mGluR1) antagonist,” Bioorganic and Medicinal
Chemistry Letters, vol. 19, no. 18, pp. 5464–5468, 2009.
[80] T. Yamasaki, M. Fujinaga, Y. Yoshida et al., “Radiosynthesis and
preliminary evaluation of 4-[18F]fluoro-N-[4- [6-(isopropyl-
amino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide
as a newpositron emission tomography ligand formetabotropic
glutamate receptor subtype 1,” Bioorganic and Medicinal
Chemistry Letters, vol. 21, no. 10, pp. 2998–3001, 2011.
[81] T. Yamasaki, M. Fujinaga, J. Maeda et al., “Imaging for
metabotropic glutamate receptor subtype 1 in rat and monkey
brains using PETwith [18F]FITM,” European Journal of Nuclear
Medicine and Molecular Imaging, vol. 39, no. 4, pp. 632–641,
2012.
[82] T. Yamasaki, M. Fujinaga, K. Kawamura et al., “In vivo mea-
surement of the affinity and density of metabotropic glutamate
receptor subtype 1 in rat brain using 18F-FITM in small-animal
PET,” Journal of Nuclear Medicine, vol. 53, no. 10, pp. 1601–1607,
2012.
[83] M. Fujinaga, T. Yamasaki, J. Yui et al., “Synthesis and evaluation
of novel radioligands for positron emission tomography imag-
ing of metabotropic glutamate receptor subtype 1 (mGluR1) in
rodent brain,” Journal of Medicinal Chemistry, vol. 55, no. 5, pp.
2342–2352, 2012.
[84] J. Yui, L. Xie, M. Fujinaga et al., “Monitoring neuroprotective
effects using positron emission tomography with [11C]ITMM,
a radiotracer for metabotropic glutamate 1 receptor,” Stroke, vol.
44, no. 9, pp. 2567–2572, 2013.
[85] J. Toyohara,M. Sakata, K. Oda et al., “Initial human PET studies
of metabotropic glutamate receptor type 1 ligand 11C-ITMM,”
Journal of Nuclear Medicine, vol. 54, no. 8, pp. 1302–1307, 2013.
[86] M. Fujinaga, T. Yamasaki, J. Maeda et al., “Development of
N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-
N-methyl-4-[11C]methylbenzamide for positron emission
tomography imaging of metabotropic glutamate 1 receptor in
monkey brain,” Journal of Medicinal Chemistry, vol. 55, no. 24,
pp. 11042–11051, 2012.
[87] T. Yamasaki, J. Maeda, M. Fujinaga et al., “PET brain kinet-
ics studies of 11C-ITMM and 11C-ITDM, radioprobes for
metabotropic glutamate receptor type 1, in a nonhuman pri-
mate,”TheAmerican Journal of Nuclear Medicine andMolecular
Imaging, vol. 4, pp. 260–269, 2014.
[88] T. Yamasaki, M. Fujinaga, J. Yui et al., “Noninvasive quantifica-
tion ofmetabotropic glutamate receptor type 1with [11C]ITDM:
a small-animal PET study,” Journal of Cerebral Blood Flow and
Metabolism, vol. 34, no. 4, pp. 606–612, 2014.
[89] R. Xu, P. Zanotti-Fregonara, S. S. Zoghbi et al., “Synthesis
and evaluation in monkey of [18F]4-Fluoro- N-methyl-N-
(4-(6-(methylamino)pyrimidin-4-yl)thiazol-2-yl)benzamide ([
18F]FIMX): a promising radioligand for PET imaging of brain
metabotropic glutamate receptor 1 (mGluR1),” Journal ofMedic-
inal Chemistry, vol. 56, no. 22, pp. 9146–9155, 2013.
[90] P. Zanotti-Fregonara, S. Zoghbi, J. S. Liow et al., “[18F]FIMX is
a promising tracer to quantify metabotropic glutamate receptor
1 (mGluR1) in human brain,” Journal of Nuclear Medicine, vol.
55, supplement 1, p. 359, 2014.
[91] T. G. Hamill, S. Krause, C. Ryan et al., “Synthesis, char-
acterization, and first successful monkey imaging studies of
metabotropic glutamate receptor subtype 5 (mGluR5) PET
radiotracers,” Synapse, vol. 56, no. 4, pp. 205–216, 2005.
[92] J.-Q. Wang, W. Tueckmantel, A. Zhu, D. Pellegrino, and A.-L.
Brownell, “Synthesis and preliminary biological evaluation of 3-
[18F] fluoro-5-(2-pyridinylethynyl)benzonitrile as a PET radio-
tracer for imaging metabotropic glutamate receptor subtype 5,”
Synapse, vol. 61, no. 12, pp. 951–961, 2007.
[93] D. F. Wong, R. Waterhouse, H. Kuwabara et al., “ 18F-FPEB,
a PET radiopharmaceutical for quantifying metabotropic glu-
tamate 5 receptors: a first-in-human study of radiochemical
18 The Scientific World Journal
safety, biokinetics, and radiation dosimetry,” Journal of Nuclear
Medicine, vol. 54, no. 3, pp. 388–396, 2013.
[94] S. M. Ametamey, L. J. Kessler, M. Honer et al., “Radiosynthesis
and preclinical evaluation of 11C-ABP688 as a probe for imaging
the metabotropic glutamate receptor subtype 5,” Journal of
Nuclear Medicine, vol. 47, no. 4, pp. 698–705, 2006.
[95] S. M. Ametamey, V. Treyer, J. Streffer et al., “Human PET
studies of metabotropic glutamate receptor subtype 5 with 11C-
ABP688,” Journal of Nuclear Medicine, vol. 48, no. 2, pp. 247–
252, 2007.
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